Geron Corporation (GERN) compared with its closest peers (KROS, CGEM, AGIO, OLMA, RIGL). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Keros Therapeutics: named as a competitor in the 10-K; Cullinan Therapeutics, Olema Pharmaceuticals, Alumis, Precigen, Veru, Bicara Therapeutics and Entrada Therapeutics share Geron's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $219.69M | 8.8 |
| Cullinan Therapeutics, Inc. (CGEM) | $1.32B | — |
| Agios Pharmaceuticals, Inc. (AGIO) | $2.00B | — |
| Olema Pharmaceuticals, Inc. (OLMA) | $787.48M | — |
| Rigel Pharmaceuticals, Inc. (RIGL) | $882.25M | 2.7 |
| Alumis Inc. (ALMS) | $1.17B | — |
| Precigen, Inc. (PGEN) | $2.45B | — |
| Veru Inc. (VERU) | $39.40M | — |
| Bicara Therapeutics Inc. (BCAX) | $1.51B | — |
| Entrada Therapeutics, Inc. (TRDA) | $264.17M | — |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
GERN overview · GERN earnings · GERN financials · GERN KPIs · GERN documents · GERN ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.